What is Evana® Heavy Period Relief 500 mg Tablets?

Evana is a pharmacy-only treatment for the reduction of Heavy Menstrual Bleeding (HMB) over several cycles.6

Evana contains 500mg tranexamic acid. Tranexamic acid is the ONLY active ingredient licensed for OTC use in HMB management and is also recommended by NICE as a first-line non-hormonal treatment option for Heavy Menstrual Bleeding2

The active ingredient in Evana Heavy Period Relief 500mg Tablets has been shown to not only reduce menstrual bleeding by up to 60%7 but also to improve quality of life by up to 83%,8 meaning you can make a real and valuable difference to the lives of your HMB patients.

An image of a packet of Evana

The overall aim of this training is to support you in providing effective, patient-specific, clinical consultations on heavy menstrual bleeding (HMB), and enable you to appropriately supply Evana Heavy Period Relief 500mg tablets (tranexamic acid), now available without prescription from pharmacies to women who are eligible.

Learning Objectives

  • To understand the definition, symptoms and causes of HMB
  • To be aware of the impact HMB has on a patient’s quality of life
  • To recognise when HMB symptoms require referral
  • To know how to manage HMB with over-the-counter (OTC) treatments
  • To understand the role and mode of action of tranexamic acid in HMB
  • To be able to recommend Evana Heavy Period Relief 500 mg tablets (tranexamic acid) appropriately
  • To be able to offer appropriate advice on the use of Evana Heavy Period Relief 500 mg tablets (tranexamic acid) in HMB.

Evana® Training Materials

Access Evana training materials online or download the hard copies for your convenience (including our pharmacist training guide, patient information leaflet, summary of product characteristics and optional checklist).

  • Essential Information

    Evana® Heavy Period Relief 500mg Tablets (Tranexamic acid) - PL 14251/0300. Indications: Reduction of heavy menstrual bleeding over several cycles in women with regular, 21-35 day cycles with no more than 3 day variation. Posology: Two tablets to be taken, 3 times a day at the onset of heavy menstrual bleeding, for a maximum of 4 consecutive days. Maximum daily dose of 8 tablets. Contraindications: Hypersensitivity to the active substance or any of the excipients, severe renal impairment, mild to moderate renal insufficiency, active thromboembolic disease, previous thromboembolic event and a family history of thrombophilia, haematuria, irregular menstrual bleeding, those taking warfarin, anticoagulants or oral contraceptives, pregnancy, fibrinolytic conditions following DIC, or history of convulsions. Precautions: Women aged over 45, those who are diabetic or obese, polycystic ovary syndrome, a family history of endometrial cancer, and those receiving unopposed oestrogen or tamoxifen, breastfeeding. Side effects: Common (≥1/100 to <1/10): Nausea, vomiting, diarrhoea. Uncommon (≥1/1,000 to <1/100): Allergic skin reactions. Very rare (<1/10,000): Hypersensitivity reactions including anaphylaxis. Frequency unknown: thromboembolic events, retinal/artery occlusion, impaired colour vision or visual disturbances, seizures.  MA holder: Manx Healthcare Ltd, Taylor Group House, Wedgnock Lane, CV34 5YA, UK. Classification: P. RRP: 18 tablets: £14.95. Date: January 2024